Sonnet BioTherapeutics Holdings, Inc.
Finalize the licensing agreement with New Life Therapeutics
Delivered after the deadline (32 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 16 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- 2 May 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects to finalize this agreement during the first quarter of 2021.”
What we found
Evidence strength A What the grades mean
The company announced an expectation to finalize the agreement in the first quarter of 2021, but filings confirm the agreement was entered into on May 2, 2021.
-
A Sonnet BioTherapeutics Holdings, Inc. 10-Q filed 2021-08-16
“On May 2, 2021, the Company entered into a License Agreement (the “New Life Agreement”) with New Life Therapeutics PTE, LTD (“New Life”).” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Transaction other
- Indicative materiality
- Medium rules
- Action
- Finalize
- Deliverable
- Licensing agreement
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Sonnet BioTherapeutics Holdings, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C106838-023910 · Corrections policy